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Abstract High concentrations of adenosine-5P-diphosphate
ADP are able to induce partial aggregation without shape
change of P2Y1 receptor-deficient mouse platelets through
activation of the P2Y12 receptor. In the present work we studied
the transduction pathways selectively involved in this phenomen-
on. Flow cytometric analyses using R-phycoerythrin-conjugated
JON/A antibody (JON/A-PE), an antibody which recognizes
activated mouse KIIbL3 integrin, revealed a low level activation
of KIIbL3 in P2Y1 receptor-deficient platelets in response to
100 WM ADP or 1 WM 2MeS-ADP. Adrenaline induced no
such activation but strongly potentiated the effect of ADP in a
dose-dependent manner. Global phosphorylation of 32P-labeled
platelets showed that P2Y12-mediated aggregation was not
accompanied by an increase in the phosphorylation of myosin
light chain (P20) or pleckstrin (P47) and was not affected by the
protein kinase C (PKC) inhibitor staurosporine. On the other
hand, two unrelated phosphoinositide 3-kinase inhibitors, wort-
mannin and LY294002, inhibited this aggregation. Our results
indicate that (i) the P2Y12 receptor is able to trigger a P2Y1
receptor-independent inside-out signal leading to KIIbL3 integrin
activation and platelet aggregation, (ii) ADP and adrenaline use
different signaling pathways which synergize to activate the
KIIbL3 integrin, and (iii) the transduction pathway triggered by
the P2Y12 receptor is independent of PKC but dependent on
phosphoinositide 3-kinase. ß 2001 Federation of European
Biochemical Societies. Published by Elsevier Science B.V. All
rights reserved.
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1. Introduction
ADP is one of the main agonists of platelet activation and
aggregation. After its release from dense granules in response
to secretory agents like thrombin or collagen, ADP acts as a
cofactor by contributing to enhancing platelet activation and
stabilizing aggregates [1]. Two G protein-coupled receptors,
P2Y1 and P2Y12, are involved in platelet aggregation in re-
sponse to ADP. The P2Y1 receptor, coupled to calcium mo-
bilization, is necessary for ADP-induced platelet shape change
and the initiation of aggregation [2,3]. The recently cloned
P2Y12 receptor [4,5], coupled to inhibition of adenylyl cyclase
(AC) through a pertussis toxin-sensitive Gi2 protein [5^7], is
responsible for completion and ampli¢cation of the platelet
response to ADP and other aggregating agents [8^10].
The generation of P2Y1 receptor-de¢cient mice has shown
that platelet aggregation in response to a usual concentration
of ADP (5 WM) is totally lost when this receptor is absent
[11,12], whereas a higher concentration of ADP (100 WM) is
able to induce partial aggregation through activation of the
P2Y12 receptor [12]. This aggregation occurs without calcium
movement or platelet shape change and leads to the formation
of small aggregates of discoid resting-like platelets [12]. Inter-
estingly, a similar aggregation without shape change in re-
sponse to a high concentration of ADP occurs in GKq-de¢-
cient mouse platelets [10] which con¢rms the involvement of
the P2Y12/Gi protein signaling pathway in this partial re-
sponse.
In the present work, as we wished to determine the speci¢c
transduction pathways involved in P2Y12 receptor-dependent
platelet aggregation, we used P2Y1 receptor-de¢cient mouse
platelets in order to study P2Y12 receptor signaling without
P2Y1 receptor transduction. Our results show that (i) ADP-
induced P2Y12 receptor activation triggers an inside-out signal
leading to activation of the KIIbL3 integrin and platelet aggre-
gation, (ii) adrenaline, which per se does not induce platelet
aggregation, although leading to inhibition of AC, strongly
potentiates this response indicating that ADP may trigger
some other transduction events, and (iii) the signaling path-
way leading to aggregation of P2Y1 receptor-de¢cient mouse
platelets clearly involves activation of a phosphoinositide
3-kinase (PI 3-kinase) but is independent of protein kinase
C (PKC).
2. Materials and methods
2.1. Materials
The ATP analogue AR-C69931MX was a generous gift from Astra
Zeneca (Loughborough, UK). ADP, 2MeS-ADP, thrombin, adrena-
line, prostaglandin E1 (PGE1), staurosporine, EGTA and human se-
rum albumin (HSA) were from Sigma-Aldrich (Saint Quentin-Falla-
vier, France). LY294002 and wortmannin were from Calbiochem
(Meudon, France). Human ¢brinogen was from Kabi (Stockholm,
Sweden) and the BCA protein assay kit from Pierce (Rockford, IL,
USA). The cAMP assay kit and carrier-free orthophosphate (32P)
were from Amersham Pharmacia Biotech (Les Ulis, France). Apyrase
was puri¢ed from potatoes as previously described [13].
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2.2. Animals
Mutant mice de¢cient in the P2Y1 receptor were produced as de-
scribed by Le¤on et al. [12] and both wild-type (WT) and knockout
mice were of 129/SvUC57BL/6 genetic background.
2.3. Platelet aggregation
Washed mouse platelets were prepared from blood (nine volumes)
drawn from the abdominal aorta of anesthetized mice into a plastic
syringe containing acid citrate dextrose anticoagulant (one volume).
Pooled blood (8 ml) was centrifuged at 1570Ug for 80 s at 37‡C and
platelet-rich plasma was removed and centrifuged at 1570Ug for 8 min
at 37‡C. The platelet pellet was washed twice in Tyrode’s bu¡er (137
mM NaCl, 2 mM KCl, 12 mM NaHCO3, 0.3 mM NaH2PO4, 1 mM
MgCl2, 2 mM CaCl2, 5.5 mM glucose, 5 mM HEPES, pH 7.3) con-
taining 0.35% HSA and ¢nally resuspended at a density of 2U105
platelets/Wl in the same bu¡er in the presence of 0.02 U/ml of the
ADP scavenger apyrase (adenosine 5P-triphosphate diphosphohydro-
lase, EC 3.6.1.5), a concentration su⁄cient to prevent desensitization
of platelet ADP receptors during storage [14]. Platelets were kept at
37‡C throughout all experiments.
Aggregation was measured at 37‡C by a turbidimetric method in a
dual-channel Payton aggregometer (Payton Associates, Scarborough,
ON, Canada). A 450 Wl aliquot of platelet suspension was stirred
at 1100 rpm and activated by addition of di¡erent agonists, with or
without antagonists, in the presence of human ¢brinogen (0.25 mg/ml)
in a ¢nal volume of 500 Wl. The extent of aggregation was estimated
quantitatively by measuring the maximum curve height above baseline
level.
2.4. cAMP measurement
A 450 Wl aliquot of washed platelet suspension was stirred at
1100 rpm in an aggregometer cuvette and reagents were added at
30 s intervals. One minute after addition of the last agonist the reac-
tion was stopped by adding 50 Wl of ice-cold 6 N perchloric acid
(PCA). cAMP was isolated from the supernatant by extraction with
a mixture of trioctylamine and freon (28/22, v/v). The upper aqueous
phase was lyophilized and the dry residue dissolved in the bu¡er
provided with the commercial cAMP radioimmunoassay kit. cAMP
was measured according to the kit instruction as previously described
[3].
2.5. Scanning electron microscopy (SEM)
A 450 Wl aliquot of platelet suspension was ¢xed at the maximum of
ADP-induced platelet aggregation (2 min after addition of ADP
100 WM for WT platelets, 6 min for P2Y1 receptor knockout mouse
platelets) by addition of an equal volume of ¢xative solution (2.5%
glutaraldehyde in 0.1 M sodium cacodylate bu¡er containing 2% su-
crose, 305 mOsm, pH 7.3) previously warmed to 37‡C. After 5 min at
37‡C, the platelets were centrifuged at 12 000Ug for 20 s and the
pellet was resuspended in ¢xative solution. The ¢xed platelets were
allowed to adhere for 45 min to coverslips preincubated with 10 Wg/ml
poly-L-lysine. The coverslips were then washed three times with 0.9%
NaCl and the platelets dehydrated in graded ethanol solutions. After
replacement of ethanol by hexadimethyldisilazane, the samples were
air-dried, sputtered with gold and examined under a Hitachi (Tokyo,
Japan) S-800 scanning electron microscope (5 kV) as previously de-
scribed [10].
Fig. 1. Partial aggregation of P2Y1 receptor-de¢cient mouse platelets induced by ADP or 2MeS-ADP is mediated by the P2Y12 receptor.
Aggregation of wild-type (WT, black curves) and P2Y1 receptor-de¢cient mouse platelets (P2Y13/3, gray curves) was measured as described
in Section 2.3 and the addition of reagents is indicated by arrows. A: Shape change and aggregation in response to 5 WM ADP is lost in
P2Y13/3 as compared to WT platelets. B: ADP 100 WM induces partial aggregation of P2Y13/3 mouse platelets relative to the control.
C: The selective P2Y12 receptor antagonist AR-C69931MX (5 WM) inhibits aggregation of WT platelets and abolishes the partial aggregation
induced by ADP 100 WM on P2Y13/3 mouse platelets. D: 2MeS-ADP 1 WM induces the same partial aggregation of P2Y13/3 platelets.
E: AR-C69931MX (5 WM) inhibits aggregation in response to 2MeS-ADP 1 WM. The tracings are representative of three independent experi-
ments giving identical results.
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2.6. Flow cytometric analysis of activation of the KIIbL3 integrin
The activation of washed platelets was assessed with R-phycoery-
thrin-conjugated JON/A antibody (JON/A-PE) which preferentially
binds to the active but not the resting form of the integrin (Bergmeier
et al., in preparation). Washed platelets (5U107/ml in Tyrode^
HEPES/1 mM CaCl2) were stimulated with 100 WM ADP in the
presence or absence of 5 WM adrenaline. JON/A-PE (5 Wg/ml) was
added to the platelets at the indicated time points after stimulation
and suspensions were incubated for 10 min at 37‡C. Data were ana-
lyzed using Cell Quest Software (FACScalibur 4C, Becton Dickinson,
Pont de Claix, France).
2.7. Measurement of protein phosphorylation
To study the phosphorylation of myosin light chain (MLC) and
pleckstrin during aggregation, platelets (8U105/Wl) were ¢rst labeled
for 90 min at 37‡C with 32P (10.5 MBq/109 platelets), in Tyrode’s
bu¡er without phosphate containing 0.35% HSA and apyrase. The
platelets were then washed in Tyrode’s bu¡er containing 0.35%
HSA and ¢nally resuspended at a density of 5U105 platelets/Wl in
Tyrode’s bu¡er containing 0.1% HSA. Platelet aggregation was
stopped at di¡erent time points by addition of 0.3 N ice-cold PCA.
The precipitated proteins were centrifuged at 12 000Ug for 4 min at
4‡C and the pellet was washed in 500 Wl of Tyrode’s bu¡er without
glucose, calcium or magnesium. After a second centrifugation at
12 000Ug for 2 min, the proteins were dissolved in 50 Wl of solubili-
zation bu¡er (50 mM Tris pH 6.8, 2 mM N-ethylmaleimide, 3% glyc-
erol, 2% SDS, 5% 2-mercaptoethanol) containing protease inhibitors
(10 Wg/ml leupeptin, 10 Wg/ml aprotinin, 10 WM aPMSF). Protein
concentration was determined by BCA, and aliquots (50 Wg) were
separated on polyacrylamide gel gradients (7.5^12%) in migration
bu¡er (25 mM Tris, 192 mM glycine, 0.1% SDS, pH 8.35). The gels
were stained with Coomassie blue, dried and labeled proteins were
located by autoradiography on L-max ¢lm (Amersham Pharmacia
Biotech, Les Ulis, France). Band densities were quanti¢ed with Quan-
tity One Software (Bio-Rad, Hercules, CA, USA).
3. Results
3.1. Partial aggregation of P2Y1 receptor-de¢cient mouse
platelets in response to a high concentration of ADP is
mediated by the P2Y12 receptor
As previously reported [12] P2Y1 receptor-de¢cient
(P2Y13/3) mouse platelets were unable to aggregate in re-
sponse to 5 WM ADP (Fig. 1A). In contrast, stimulation with
100 WM ADP (Fig. 1B) or 1 WM 2MeS-ADP (Fig. 1D) re-
sulted in partial aggregation which reached 29.0 þ 2.7% for
ADP and 28.4 þ 3.5% for 2MeS-ADP, with no turbidimetri-
cally measurable e¡ect on shape change (n = 3). Control ag-
gregation of WT platelets reached 77.9 þ 3.1% (Fig. 1B). The
time course of this partial aggregation was slow and attained
its maximum only after 6^7 min, whereas aggregation of WT
platelets was maximal at 2 min (Fig. 1B). Aggregation of
P2Y13/3 mouse platelets in response to ADP or 2MeS-
ADP (100 WM and 1 WM respectively) was abolished by
5 WM AR-C69931MX (Fig. 1C,E), a selective P2Y12 receptor
antagonist [15], indicating its dependence on the P2Y12 recep-
tor.
Fig. 2. P2Y12 receptor-mediated aggregation of P2Y13/3 platelets occurs through activation of the KIIbL3 integrin. A: RAM-2 antibody
(1 Wg/ml) against mouse KIIbL3 integrin blocks aggregation of P2Y13/3 or WT platelets induced by 100 WM ADP. B: JON/A-PE, which pref-
erentially binds to the active form of the integrin, was used to evaluate KIIbL3 integrin activation. As indicated on the left, JON/A-PE was
added to activated platelets at di¡erent time points after addition of ADP (100 WM) and samples were incubated for 10 min at 37‡C. JON/A-
PE binding to WT and P2Y13/3 platelets was analyzed on a FACScalibur.
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3.2. P2Y12 receptor activation leads to exposure of the
KIIbL3 integrin
RAM.2, a rat polyclonal antibody against mouse KIIbL3
integrin known to inhibit mouse platelet aggregation [10],
was added to the platelet suspension 1 min before ADP. It
prevented aggregation of WT or P2Y13/3 platelets induced
by 100 WM ADP (Fig. 2A), showing that P2Y12 receptor-de-
pendent aggregation occurred through KIIbL3 activation. The
kinetics of KIIbL3 integrin activation on WT and P2Y13/3
platelets were assessed by £ow cytometric analysis of binding
of JON/A-PE, a rat monoclonal antibody derivative which
preferentially recognizes activated mouse KIIbL3 integrin
(Bergmeier et al., in preparation). In WT platelets, KIIbL3 in-
tegrin activation occurred rapidly and was reversible, reaching
its maximum 10 s after stimulation with ADP (100 WM) (Fig.
2B). In comparison, KIIbL3 integrin activation of stimulated
Fig. 3. Adrenaline potentiates the responses of P2Y13/3 platelets to ADP. A: P2Y13/3 platelets were stimulated with ADP (5 or 100 WM) in
the presence of increasing concentrations of adrenaline. Adrenaline potentiates the aggregation induced by 100 WM ADP in a dose-dependent
manner (left). Addition of adrenaline (s 0.1 WM) restores aggregation in response to 5 WM ADP (right). The tracings are representative of two
separate experiments giving identical results. B: Adrenaline (5 WM) enhances the binding of JON/A-PE to ADP-activated mouse KIIbL3 integrin
on P2Y13/3 platelets. At the indicated time points, JON/A-PE was added to P2Y13/3 platelets activated with 100 WM ADP (left panel) or
100 WM ADP in combination with 5 WM adrenaline (right panel). Samples were incubated for 10 min at 37‡C and analyzed directly. C: WT
(a) and P2Y13/3 (b^f) mouse platelets were prepared for SEM as described in Section 2.5. ADP (5 WM) induces shape change and aggregation
in WT platelets (a), whereas P2Y13/3 platelets remain single and discoid after stimulation with 5 WM ADP (b) or 100 WM adrenaline alone
(c). ADP (100 WM) induces small aggregates of discoid P2Y13/3 platelets (d) and the size of these aggregates is increased in the presence of
100 WM adrenaline (f). Adrenaline (1 WM) restores aggregation of P2Y13/3 platelets stimulated with 5 WM ADP (e). Magni¢cation: U6000.
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P2Y13/3 platelets was strongly reduced. Although activation
was complete at 10 s as in the WT, it remained irreversible
during the 10 min of observation which correlates with the
aggregation tracings (Fig. 2B). The apparent discrepancy be-
tween the slow onset of aggregation and KIIbL3 integrin acti-
vation is mainly due to a lack of sensitivity of the turbidimet-
ric method which fails to detect small aggregates. In order to
address this issue, single platelet counting was used to evalu-
ate platelet aggregation to 100 WM ADP. A 7% decrease in the
platelet count was observed as soon as 40 s after addition of
Fig. 3 (continued).
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ADP, reaching 52% at 10 min. These experiments have been
repeated two times and gave identical results.
3.3. Potentiation of P2Y12 receptor-mediated platelet
aggregation by adrenaline
Adrenaline is not in itself an aggregating agent [16,17] and
at concentrations of up to 1 mM was not able to induce
aggregation of either WT or P2Y13/3 mouse platelets (data
not shown). On the other hand, adrenaline potentiated
P2Y13/3 mouse platelet aggregation in response to either
ADP 100 WM (Fig. 3A, left panel) or 2MeS-ADP 1 WM
(data not shown) in a dose-dependent manner from 1 to 100
WM. Moreover, addition of adrenaline at a concentration as
low as 1 WM allowed the aggregation of P2Y13/3 mouse
platelets in response to 5 WM ADP (Fig. 3A, right panel).
These results suggest that ADP and adrenaline activate signal-
ing pathways which potentiate each other, whereas adrenaline
alone is not able to trigger an inside-out signal leading to
platelet aggregation like ADP does. Flow cytometric analysis
further showed that 5 WM adrenaline potentiated KIIbL3
integrin activation on P2Y13/3 platelets stimulated with
100 WM ADP (Fig. 3B) or 1 WM 2MeS-ADP (data not
Fig. 5. P2Y12 receptor-mediated aggregation of P2Y13/3 platelets occurs without phosphorylation of pleckstrin or MLC. The time course of
the phosphorylation of pleckstrin and MLC was determined in WT and P2Y13/3 platelets activated with 100 WM ADP. A: Representative
autoradiography showing that 100 WM ADP induces early phosphorylation of pleckstrin in WT platelets (upper panel) but not in P2Y13/3
platelets (lower panel). B: WT (open bars) and P2Y13/3 platelets (black bars) were stimulated with 100 WM ADP. At the indicated times, the
reaction was stopped and phosphorylated proteins were isolated and separated by SDS^PAGE (7.5^12%). The labeled proteins were located by
autoradiography and quanti¢ed as described in Section 2.7. Curves are representative of two independent experiments giving similar results.
Fig. 4. Inhibition of AC by ADP and adrenaline in P2Y1 receptor-de¢cient mouse platelets. Inhibition of AC activity was measured in platelets
prestimulated with PGE1 10 WM as described in Section 2. ADP (5 or 100 WM), adrenaline (100 WM), or a combination of these two agonists
decreased cAMP levels in prestimulated platelets to the same extent. Data are the mean þ S.E.M. from three separate experiments. *P6 0.05.
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shown). Hence, the potentiating e¡ect of adrenaline on plate-
let aggregation results in stronger activation of the KIIbL3
integrin.
3.4. P2Y12 receptor-dependent aggregation occurs without
platelet shape change
SEM showed that P2Y13/3 platelets stimulated with 5 WM
ADP (Fig. 3Cb) or 100 WM adrenaline (Fig. 3Cc) conserved
the typical morphology of discoid resting platelets, in contrast
to the large aggregates of packed cells with membrane extru-
sions formed by WT platelets activated with 5 WM ADP (Fig.
3Ca). In P2Y13/3 platelets, 100 WM ADP induced the for-
mation of small aggregates of platelets which have not
changed their shape (Fig. 3Cd). In the presence of 1 WM
adrenaline, 5 WM ADP induced some similar small aggregates
of discoid platelets (Fig. 3Ce). The association of 100 WM
adrenaline and 100 WM ADP induced the formation of larger
aggregates (Fig. 3Cf). The potentiating e¡ect of adrenaline on
ADP-induced platelet aggregation was not accompanied by
shape change in P2Y13/3 mouse platelets.
3.5. Inhibition of AC by ADP cannot explain P2Y12
receptor-mediated aggregation
ADP (5 or 100 WM) or adrenaline (up to 100 WM) decreased
cAMP accumulation in PGE1-prestimulated platelets to the
same extent (Fig. 4), suggesting that a lowering of cAMP
levels is not su⁄cient to explain the P2Y12 receptor-mediated
aggregation induced by 100 WM ADP in accordance with
results obtained in GKq-de¢cient mouse platelets [10]. A com-
bination of 5 WM adrenaline and 100 WM ADP likewise did
not inhibit cAMP levels signi¢cantly more than either agonist
alone. Thus, adrenaline must potentiate the e¡ect of ADP
Fig. 6. Staurosporine does not a¡ect P2Y12 receptor-mediated platelet aggregation. Aggregation of P2Y13/3 mouse platelets was induced by
addition of 100 WM ADP (A), 5 WM adrenaline and 100 WM ADP (B) or 0.1 U/ml thrombin (C). The platelets were previously treated with ei-
ther vehicle or 1 WM staurosporine for 30 min. A, B: Staurosporine does not modify the response of P2Y13/3 platelets to 100 WM ADP,
alone or in the presence of 5 WM adrenaline. C: P2Y13/3 platelet aggregation induced by 0.1 U/ml thrombin is decreased by staurosporine.
The tracings are representative of two independent experiments giving identical results.
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through some transduction pathway di¡erent from AC inhi-
bition.
3.6. P2Y12 receptor-mediated platelet aggregation is not
accompanied by phosphorylation of MLC and pleckstrin
The global phosphorylation of platelet proteins during ag-
gregation showed that aggregation of WT platelets in re-
sponse to 100 WM ADP was accompanied by phosphorylation
of pleckstrin and MLC (Fig. 5). This phosphorylation was
reversible and reached a maximum at 20 s. In contrast, no
phosphorylation of these two proteins was observed during
P2Y12 receptor-mediated aggregation. Moreover, despite its
potentiating e¡ect on P2Y12 receptor-mediated aggregation
(Fig. 3), 5 WM adrenaline in combination with 100 WM
ADP did not induce MLC or pleckstrin phosphorylation in
P2Y13/3 mouse platelets (data not shown). The phosphory-
lation of MLC and pleckstrin therefore does not seem to be
involved in the signaling pathway leading to P2Y12 receptor-
mediated aggregation or its potentiation by adrenaline.
3.7. P2Y12 receptor-mediated platelet aggregation is
independent of PKC activation
To test the possible involvement of PKC in P2Y12 receptor-
mediated aggregation, we used the PKC inhibitor staurospo-
rine. In P2Y13/3 platelets, 1 WM staurosporine had no e¡ect
on the partial aggregation induced by 100 WM ADP (Fig. 6A),
Fig. 7. P2Y12 receptor-mediated platelet aggregation involves activation of PI 3-kinase. A: P2Y13/3 platelets treated for 1 min with either ve-
hicle (upper tracing), 25 WM LY294002 (middle tracing) or 100 nM wortmannin (lower tracing) were stimulated with 100 WM ADP (left panel)
or with 5 WM ADP and 5 WM adrenaline (right panel). Partial aggregation in response to 100 WM ADP was abolished by both inhibitors of PI
3-kinase. The tracings are representative of four separate experiments. B: Flow cytometric analysis of the inhibitory e¡ect of LY294002 (25 WM)
on JON/A-PE binding to P2Y13/3 platelets stimulated with 100 WM ADP in the presence or absence of 5 WM adrenaline. JON/A-PE was
added to activated platelets 10 s after addition of agonist(s) and samples were incubated for 10 min at 37‡C. Mean log £uorescence intensity of
JON/A-PE bound to resting (gray curve) and activated (solid line) platelets was measured in the absence (left panel) or presence (right panel)
of 25 WM LY294002.
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or on its potentiation by adrenaline (Fig. 6B), but diminished
thrombin-induced aggregation in WT mouse platelets (Fig.
6C). Hence P2Y12-mediated platelet aggregation does not de-
pend on PKC activation.
3.8. P2Y12-mediated platelet aggregation involves PI 3-kinase
activation
The two unrelated PI 3-kinase inhibitors, LY294002
(25 WM) and wortmannin (100 nM), both abolished aggrega-
tion induced by 100 WM ADP alone (Fig. 7A, left panel) or by
5 WM ADP in the presence of 5 WM adrenaline (Fig. 7A, right
panel) in P2Y13/3 platelets. Flow cytometric analysis of
P2Y1 receptor-de¢cient platelets showed that preincubation
with the PI 3-kinase inhibitor LY294002 (25 WM) abolished
KIIbL3 integrin activation induced by 100 WM ADP and
strongly diminished its activation induced by 100 WM ADP
in combination with 5 WM adrenaline (Fig. 7B). These results
clearly demonstrate that PI 3-kinase activation is involved in
P2Y12 receptor-mediated inside-out signaling.
4. Discussion
The aim of the present work was to study the transduction
pathways selectively involved in P2Y12 receptor-mediated ag-
gregation in platelets lacking the P2Y1 receptor. In a previous
report, we showed that aggregation of P2Y1 receptor-de¢cient
mouse platelets in response to 100 WM ADP occurred in the
absence of calcium movement and platelet shape change [12].
This aggregation has a pro¢le very di¡erent from that of the
WT platelet aggregation induced by ADP. It is of low ampli-
tude and slow, reaching its maximum only after 6^7 min (Fig.
1B). However, it is dependent on KIIbL3 integrin activation, as
shown by £ow cytometric monitoring of the JON/A-PE anti-
body recognizing the activated integrin. Activation of the
KIIbL3 integrin following ADP stimulation was low in
P2Y13/3 as compared to WT platelets, which correlates
with the weak pro¢le of P2Y12 receptor-mediated aggregation.
Adrenaline is known to potentiate platelet functions and
downregulate AC activity in a similar manner to ADP [16].
ADP 5 or 100 WM inhibited AC to the same extent (Fig. 4),
while 100 WM but not 5 WM ADP induced P2Y12 receptor-
mediated platelet aggregation in P2Y1-de¢cient platelets.
These results indicate that inhibition of AC by itself is not
su⁄cient to trigger aggregation of P2Y1-de¢cient platelets in
response to ADP and are in agreement with earlier studies
[18,19]. These results also suggest that activation of the
P2Y12 receptor triggers some additional events distinct from
those induced by K2-adrenergic receptor activation. Combina-
tion of 5 WM adrenaline and 100 WM ADP did not further
decrease cAMP levels as compared to 100 WM ADP alone but
greatly potentiated aggregation suggesting that the potentiat-
ing e¡ect of adrenaline on P2Y12 receptor-mediated aggrega-
tion is not due to inhibition of AC. It was recently reported
[20] that speci¢c disruption of the GKz subunit gene resulted
in severe impairment of the ability of adrenaline to potentiate
aggregation and inhibit AC, suggesting that the K2-adrenergic
receptor prefers Gz to other members of the Gi family ex-
pressed in platelets. Concerning the P2Y12 receptor, it would
appear to couple mainly to a Gi2 protein. This was ¢rst shown
by speci¢c 4-azidoanilido-[K-32]GTP photolabeling of Gi2 in
platelets stimulated with ADP [6] and has since been con-
¢rmed in GKi2-de¢cient mice, which display impairment of
ADP-induced platelet aggregation and AC inhibition [7].
The overall ¢ndings therefore suggest that the P2Y12 receptor
associates preferentially with a Gi2 protein to trigger KIIbL3
integrin activation and aggregation, whereas the K2-adrenergic
receptor associates more readily with a Gz subtype which
cannot transmit such a message but could be responsible for
its potentiation. Another possibility would be that the P2Y12
receptor is linked to some other signaling pathway in addition
to Gi2.
Two polypeptides of 20 kDa (MLC) and 45^47 kDa (pleck-
strin) display increased phosphorylation after stimulation of
WT mouse platelets with ADP (Fig. 5). In contrast, increased
phosphorylation of these two proteins was not observed in
P2Y13/3 mouse platelets stimulated by ADP (Fig. 5), thus
MLC and pleckstrin phosphorylations are not involved in
P2Y12-dependent platelet aggregation. MLC is involved in
platelet shape change [21] and its absence of increased phos-
phorylation is in accordance with the absence of shape change
during P2Y12 receptor-mediated aggregation. Since pleckstrin
was likewise not phosphorylated during P2Y12-dependent ag-
gregation, it appears that the P2Y1 receptor is responsible for
this e¡ect. This result was con¢rmed by the use of the selective
P2Y1 receptor antagonist, MRS2179 [22], which totally inhib-
ited pleckstrin phosphorylation induced by ADP in WT
mouse platelets while AR-C69931MX, the selective P2Y12 re-
ceptor antagonist [15], did not decrease it signi¢cantly (data
not shown). Moreover, the PKC inhibitor staurosporine did
not a¡ect P2Y12-dependent aggregation. These results suggest
that PKC does not participate in P2Y12 receptor signaling. In
addition, the potentiating e¡ect of adrenaline on P2Y12-medi-
ated aggregation was neither accompanied by an increase in
pleckstrin phosphorylation (data not shown) nor inhibited by
staurosporine (Fig. 6), indicating that PKC is not involved in
potentiation of platelet functions through the K2-adrenergic
receptor.
Activation of PI 3-kinase following its translocation to the
cytoskeleton has been shown to stabilize platelet aggregates
[23,24]. Trumel et al. [9] have clearly demonstrated that the
P2Y12 receptor itself is responsible for stabilization of platelet
aggregates induced by PAR-1 thrombin receptor activation in
a PI 3-kinase-dependent manner. This stabilization seems to
be linked to the late production of phosphatidylinositol 3,4-
bisphosphate. Our results using LY294002 and wortmannin
(Fig. 7) show that PI 3-kinase activity is required for P2Y12
receptor-mediated platelet aggregation. Interestingly PI 3-ki-
nase inhibitors abolished both P2Y12-dependent platelet ag-
gregation and KIIbL3 integrin activation in response to ADP
100 WM (Fig. 7) suggesting that PI 3-kinase activity is required
upstream of integrin activation. Since LY294002 and wort-
mannin do not show selectivity upon PI 3-K subtypes the
question remains as to which subtype(s) of enzyme is (are)
involved in this activation. Several studies have described a
platelet PI 3-kinase activity which is regulated by GLQ oligo-
mers [25]. The monomeric p110Q PI 3-kinase [26] has been
shown to be directly activated by GLQ oligomers in vitro
and could thus play a role in P2Y12 receptor signaling. Sel-
heim et al. showed recently that adrenaline was able to sustain
SFRLLN-induced human platelet aggregation in an ADP and
PI 3-K-independent manner. However, adrenaline could po-
tentiate phosphatidylinositol 3,4-bisphosphate formation, but
this e¡ect was dependent on secreted ADP [27]. All these data
suggest that in P2Y12 receptor-dependent platelet aggregation
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adrenaline potentiates a PI 3-kinase activity that has been
triggered by ADP. Analysis of the PI 3-kinase products,
namely phosphatidylinositol 3,4-bisphosphate and phosphati-
dylinositol 3,4,5-trisphosphate, in the course of ADP-depen-
dent aggregation of P2Y1-de¢cient mouse platelets will be
helpful in order to determine which PI 3-kinase subtype is
involved downstream of P2Y12 receptor activation.
In conclusion, the present results demonstrate that the
P2Y12 receptor is able to trigger a PI 3-kinase-dependent in-
side-out signal leading to partial aggregation of P2Y1 recep-
tor-de¢cient mouse platelets.
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